Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from...

Area of Science:

• Dermatology
• Pharmacology
• Real-world evidence

Background:

• Limited real-world data exists comparing biologic treatments for moderate-to-severe psoriasis.
• Understanding adherence and persistence across different biologics is crucial for effective clinical management.

Purpose of the Study:

• To compare the persistence and adherence of ixekizumab (IXE) against other commonly prescribed biologics for psoriasis.
• To evaluate the duration of monotherapy for IXE versus alternative biologic treatments.

Main Methods:

• Retrospective analysis of IBM MarketScan® databases for patients with psoriasis initiating new biologic treatments.
• Inverse probability of treatment weighting (IPTW) was used to balance patient characteristics for comparative analysis.
• Outcomes assessed included medication persistence, adherence, and time on monotherapy at 1-year and up to 3-year follow-ups.

Main Results:

• Patients initiating ixekizumab (IXE) had higher rates of prior biologic use compared to other biologics.
• IXE showed statistically significant greater persistence and adherence than adalimumab (ADA), etanercept (ETN), secukinumab (SEC), and ustekinumab (UST) over 1 to 3 years.
• IXE also demonstrated a longer duration of monotherapy compared to all other evaluated biologics.

Conclusions:

• Ixekizumab (IXE) treatment is associated with superior real-world persistence and adherence compared to other commonly used biologics for moderate-to-severe psoriasis.
• Patients treated with IXE remained on monotherapy longer, suggesting improved long-term treatment effectiveness and patient management.